Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 4
Submit an article Journal homepage
25
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Separating Graft-versus-tumor from Graft-versus-host Reactions

A.B.-T. Fassas Myeloma and Transplantation Research Center, Slot #776, University of Arkansas for Medical Sciences, 4301 W. Markham, Little Rock, AR 72205, USA
,
C. Morris Myeloma and Transplantation Research Center, Slot #776, University of Arkansas for Medical Sciences, 4301 W. Markham, Little Rock, AR 72205, USA
,
A. Badros Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA
,
F. Van Rhee Myeloma and Transplantation Research Center, Slot #776, University of Arkansas for Medical Sciences, 4301 W. Markham, Little Rock, AR 72205, USA
&
G. Tricot Myeloma and Transplantation Research Center, Slot #776, University of Arkansas for Medical Sciences, 4301 W. Markham, Little Rock, AR 72205, USA
Pages 725-733 | Published online: 01 Jul 2009

  • Weiden. P.L. and Horowitz, M.M. (1990) Graft-vs-leukemia effect in clinical bone marrow transplantation", In: Burakoff, S.J., Deeg, H.J., Ferrara, J.L.M. and Atkinson, K., eds. Graft-Versus-Host Disease (Marcel Dekker, New York), pp 691-703.
  • Train, R.L., Johnson, B.D., McCabe, C. and Weiler, M.B (1997) "Graft versus leukemia", In: Ferrara, J.L.M., Deeg, H.J and Burakoff, S.J., eds. Graft Versus Host Disease: Immunology. Pathophysiology, and Treatment (Marcel Dekker, New York), pp 385-423.
  • Barren, J. and Malkovska, V. (1996) "The graft-versus-leukemia effect", Curr. Opin. Oncol. 8, 89-95.
  • Weiden, P.L., Sullivan, K.M., Rournoy, N., et al. (1981) "The Seattle marrow transplant team: antileukemic effect of chronic graft-versus-host disease, contribution to improved survival after allogeneic marrow transplantation", N. Engl. J. Med. 304, 1529-1533.
  • Gale, R.P. and Champlin, R.E. (1984) "How does bone-marrow, transplantation cure leukaemia?", Lancet 2, 28-30.
  • Horowitz, M.M., Gale, R.R. Sondel, P.M., et al. (1990) "Graft-versus-leukemia reactions after hone marrow transplantation", Blood 75, 555-562.
  • Collins, R.H., Shpilberg, O., Drohyski, W.R., et al. (1997) "Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation", J. Clin. Oncol. 15, 433-444.
  • Kolb, H.J., Schattenberg, A., Goldman, J.M., et al. (1995) "Graft-versus-leukemia effect of donor lymphocyte transfusions in morrow grafted patients", Blood 86, 2041-2050.
  • Alyea, E.P., Soiffer, R.J., Canning, C., et al. (1998) "Toxicity and eflicacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant", Blood 91, 3671-3680.
  • Drobyski, W.R., Keever, C.A., Roth, M.S., et al (1993) "Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose", Blood 82, 231O-2318.
  • Ferrara, J.L. and Deeg, H.J. (1991) "Graft-versus-host disease", N. Engl. J. Med. 324, 667-674.
  • Kienger, W., Hill, G.R. and Ferrara, J.L. (1997) "Cytokine cascades in acute graft-versus-host disease", Transplantation 64, 553-558.
  • Kagi, D. Vignaux, E. Ledermann, B., et al. (1994) "Fas and perform pathways as major mechanisms of T cell medicated cytotoxicity", Science 265, 528-530.
  • Lowin, B., Hahne, M., Mattmann, C., et al. (1994) "Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways", Nature 370, 650-652.
  • Male, G., Cobbold, S. and Waldmann, H. (1988) "T-cell depletion with CAMPATH-1 in allogeneic hone marrow transplantation", Transplantation 45, 753-759.
  • Antin, J.H., Bieter, B.E., Smith, B.R., et al. (1991) "Selective depletion of bone marrow T- lymphocytes with anti-CDS monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies", Blood 78, 2139-2149.
  • Marmont, A.M., Horowitz, M.M., Gale, R.P. et al. (1991) "T-cell depletion of ULA-identical transplants in leukemia", Blood 78, 2120-2130.
  • Shapiro, R.S. McClain, K., Frizzera, G., et al. (1988) "Epstein-Barr virus associated B-cell lymphoproliferative disorders following hone marrow transplantation", Blood 71, 19234-19243.
  • Zulter, M.M., Martin, P.J., Sale, G.E., et al. (1988) "Epstein-Barr virus lymphoproliferation after bone marrow transplantation", Blood 72, 520-529.
  • Truitt, R.L. and Atasoylu, A. (1991) "Contribution of CD4+ and CDS+ T-cells to graft-versus-host disease and graft-versus leukemia reactivity after transplantation of MIIC-compatible bone marrow", Bone Marrow Transplant. 8, 51-58.
  • Slavin, S., Ackerstein, A., Naparstek, E., et al. (1990) "The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?", Bone Marrow Transplant. 6, 155-161.
  • Komgold, R. (1993) "Biology of graft-vs-host disease", Am. J. Pediatr. Hematol. Oncot. 15, 18-27.
  • Soiffer, R.J., Gonin, R., Murray, C., et al. (1993) "Prediction of graft-versus host disease by phenotypic analysis of early immune reconstitution after DC6-depleted allogeneic bone marrow transplantation", Blood 82, 2216-2223.
  • Nimer, S.D., Giorgi, J. and Gajewski, J.R. (1994) "Selective depiction of CDS+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial", Transplantation 57, 82-87
  • Giralt, S., Hester, J., Huh, Y., et al. (1995) "CDS-depleted donor lymphocyte infusion is treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation", Blood 86, 4337-4343.
  • Shimom, A., Anderlini, P., Andersson, B., et al. (1999) "ODS-deplete donor lymphocyte infusion (DLI) for the treatment of CCML relapse alter allogeneic transplant: long term follow up and factors predicting outcome", Blood 94, 700a.
  • Soiffer, R.J., Fairclough, D., Robertson, M., et al. (1997) "CD6-depleted allogeneic hone marrow transplantation for acute leukemia in first complete remission", Blood 89, 3039-3047.
  • Soiffer, R.J., Freedman, A.S., Neuberg, D. et al. (1998) "CD6+ T-cell depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma", Bone Marrow Transplant. 21, 1177-1181.
  • Soiffer, R.J., Weller, F., Alyea, R.P., et al. (2001) "CD6+ donor marrow T-cell depletion as the sole for of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors", J. Clin. Oncol. 19, 1152-1159.
  • Sullivan, K.M. Storb, R., Buckner, C.D., et al. (1989) "Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasm", N. Engl. J. Mwd. 320, 828-834.
  • van der Straaten, H.M., Fijoheer, R., Dekker, A., et al. (2001) "Relationship between graft-versus-host disease and graft-versus-leukaemia in partial T-cell-depleted bone marrow transplantation", Br. J. Haematol. 114, 31-35.
  • Atkinson, K., Horowitz, M.M., Gale, R.P., et al. (1990) "Risk factors for chronic graft-versus-host disease after HLA-identcal sibling bone marrow transplantation", Blood 75, 2459-2464.
  • Dazzi, F., Sydlo. R.M. and Goldman, J.M. (1999) "Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: where we now stand", Exp. Hematol. 27, 1477-1486.
  • Mackinnon, S., Papadopoulos, E.B., Carabasi, M.N., et al. (1995) "Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-host disease", Blood 86, 1261-1268.
  • Dazzi, F. Szydlo, R.M., Craddock, N.C., et al. (2000) "Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia", Blood 95, 67-71.
  • Bacigalupo, A., Soracco, M., Vassallo, F., et al. (1997) "Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation", Bone Morrow Transplant. 819, 927-932.
  • Guinan, E.G., Boussiotis, V.A., Neubert, D., et al. (1999) "Transplantation of anergic histoincompatible bone marrow allografts", N. Engl. J. Med. 340, 1704-1714.
  • Steinman, R.M. and Young, J.W. (1991) "Signals arising from antigen-presenting cells", Curr. Opin. Immunol. 3, 361-372.
  • Bretscher, P. and Cohn, M. (1970) "A theory of self-nonself discrimination", Science 169, 1042-1049.
  • Munshi, N.C., Govindarajan, R., Drake, R., et al. (1997) "Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir", Blood 89, 1334-1340.
  • Bonini, C. Ferrari, G., Verzelelu, S., et al. (1997) "HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia", Science 276, 1719-1724.
  • Tiberghien, P., Ferrand, C., Lioure, B., et al. (2001) "Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft", Blood 97, 63-72.
  • Johnson, B.D., Drobyski, W.R. and Truitt, R.L. (1993) "Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an and leukemia reaction without graft-versus-host disease", Bone Marrow Transplant. 11, 329-336.
  • Johnson, B.D. and Truitt, R.L. (1995) "Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease", Blood 85, 3302-3312.
  • Naparstek, E., Or, R., Nagler, A., et al. (1995) "T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration donor's peripheral blood lymphocytes for prevention of relapse", Br. J. Haemalol. 89, 506-515.
  • Barren, A.J., Mavroudis, D., Tisdale, J., et al. (1998) "T-cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect", Bone Marrow Transplant. 21, 543-551.
  • Horowitz, M.M., Rowlings, P.A. and Passweg, J.R. (1996) "Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry", Bone Marrow Transplant. 17(Supp. 3), S5-S6.
  • Clift, R.A. and Storb, R. (1996) "Marrow transplantation for CML: the Seattle experience", Bone Marrow Transplant. 17(Suppl. 3), S1-S3.
  • Clift, R.A., Buckner, C.D., Thomas, E.D., et al (1994) "Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia", Blood 84, 4368-4373.
  • Working Party Chronic Leukaemia of the European Group for Blood and Bone Marrow Transplantation. Gratwohl, A. and Hermans, J. (1996) "Allogeneic bone marrow transplantation for chronic myeloid leukaemia", Bone Marrow Transplant. 17(Suppl. 3), S7-S9.
  • Gahrton, G. (1996) "Allogeneic bone marrow transplantation in multiple myeloma", Br. J. Haematol. 92, 251-254.
  • Socie'te' Francaise de Greffe de MoelleSutton, L., Chastang, C., Ribaud, P., et al. (1996) "Factors influencing outcome in de nova myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study", Blood 88, 358-365.
  • Boranic, M. (1981) "Controlled graft-versus-host reaction in the treatment of leukemia in mice", In: Okunewick, J.P. and Meredith, R.P., eds. Graft-Versus-Leukemia in Man and Animal Models (CRC Press. Boca Raton), pp 117-126.
  • Boranic, M. (1988) "Graft versus leukemia in bone marrow transplantation", Blood 57, 57-63.
  • Boranic, M. and Tonkovic, J. (1971) "Time pattern of the antileukemic effect of graft-versus-host reaction", Cancer Res. 31, 1140-1148.
  • Lazarus, H.M., Coccia, P.E. Herzig, R.H., et al. (1984) "Incidence of acute graft-versus-host disease with and without methotrexate prophylaxis in allogeneic bone marrow transplant patients", Blood 64, 215-220.
  • Sullivan, K.M., Deeg, H.J., Sanders, J., et al. (1986) "Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation", Blood 67, 1172-1175.
  • Passas, A., Rapoport, A., Coltier-Fox, M., et al. (2000) "Encouraging preliminary results in 12 patients with high-risk haematological malignancies by omitting graft-versus-host disease prophylaxis after allogeneic transplantation", Br. J. Haematol. 111, 662-667.
  • Krofer, N., Zabelna, T., Krüger, W., et al. (2001) "Anri-thymocyteglobulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GVHD) in allogeneic stem cell transplantation from unrelated donors", Ann. Hematol. 80, 209-215.
  • Bacigalupo, A., Van Lint, M.T., Occhini, F., et al. (1991) "Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia", Blood 77, 1423-1428.
  • Locatelli, R. Zacca, M., Rondelli, R., et al. (2000) "Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial", Blood 95, 1572-1579.
  • Carlens, S., Aschan, J., Remberger, M., et al. (1999) "Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia", Bone Marrow Transplant. 24, 629-635.
  • Mavroudis, D.A., Dermime, S., Molldrem, J., et al. (1998) "Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus leukaemia reactions", Br. J. Haematal 101, 565-570.
  • Kaminski, E., Hows, J., Man, S., et al. (1989) "Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation", Transplantation 48, 608-613.
  • Roosnek, E., Hogendijk, S., Zawadynski, S., et al. (1993) "The frequency of pretransplant donor cytotoxic T cell precursors with anti-host specificity predicts survival of patients transplanted with bone marrow from donors other than HLA-idetical siblings", Transplantation 56, 691-696.
  • Falkenburg, J.H.F., Wafelman, A.R., Joosten, P., et al. (1999) "Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes", Blood 94, 1201-1208.
  • Champlin, R., Khouri, I., Shimoni, A., et al. (2000) "Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy", Br. J. Haematol. 111, 18-29.
  • Hill, G.R. and Ferrara, J.L.M. (2000) "The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation", Blood 95, 2754-2759.
  • Kjijanovski, O.L., Hill, G.R., Cooke, K.R., et al. (1999) "Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease", Blood 94, 825-831.
  • Hill, G.R., Cooke, K.R., Teshima, T., et al (1998) "Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation", J. Clin. Investig. 102, 115-123.
  • Cooke, K.R., Gerbitz, A., Crawford, J.M., et al. (2001) "LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation", J. Clin. Investig. 107, 1581-1589.
  • Schmaltz, C., Alpdogan, O., Homdasch, K.J., et al. (2001) "Differential use of Fas ligand and perform cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect", Blood 97, 2886-2895.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.